标题
Myeloma Bone Disease: A Comprehensive Review
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 12, Pages 6208
出版商
MDPI AG
发表日期
2021-06-09
DOI
10.3390/ijms22126208
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
- (2020) Stefania Raimondo et al. Cancers
- The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
- (2020) Eugenio Morelli et al. Cancers
- Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis
- (2019) Stefania Raimondo et al. Journal of Hematology & Oncology
- Exosomal circRNAs: biogenesis, effect and application in human diseases
- (2019) Yangxia Wang et al. Molecular Cancer
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2018) Kenneth Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- (2018) Noopur Raje et al. LANCET ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis
- (2018) Bingzong Li et al. ONCOGENE
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
- (2017) Andrew L. Himelstein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging treatment approaches for myeloma-related bone disease
- (2017) Maria Gavriatopoulou et al. Expert Review of Hematology
- Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma
- (2016) Ailing Lu et al. AMERICAN JOURNAL OF PATHOLOGY
- CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
- (2016) James R. Berenson et al. BLOOD
- Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
- (2016) J. Delgado-Calle et al. CANCER RESEARCH
- Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
- (2016) Nicola Amodio et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease
- (2016) Hui Liu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Current Controversies in the Management of Myeloma Bone Disease
- (2016) Rebecca Silbermann et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Myeloma cell-derived Runx2 promotes myeloma progression in bone
- (2015) T. N. Trotter et al. BLOOD
- Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
- (2015) Oddrun Elise Olsen et al. Cell Communication and Signaling
- Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
- (2015) N. Raje et al. CLINICAL CANCER RESEARCH
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation
- (2015) Lavinia Raimondi et al. Oncotarget
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues
- (2014) Tanwarat Sanvoranart et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
- (2014) P. G. Richardson et al. BLOOD
- Sotatercept in patients with osteolytic lesions of multiple myeloma
- (2014) Kudrat M. Abdulkadyrov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro
- (2014) Arnold Bolomsky et al. EXPERIMENTAL HEMATOLOGY
- Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
- (2014) Yali Li et al. LEUKEMIA RESEARCH
- Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells
- (2013) Yong Wan et al. BONE
- Repetitively dosed docetaxel and153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
- (2013) Karen A. Autio et al. CANCER
- Cellular Mechanisms of Multiple Myeloma Bone Disease
- (2013) Angela Oranger et al. Clinical & Developmental Immunology
- New Strategies in the Treatment of Multiple Myeloma
- (2013) N. C. Munshi et al. CLINICAL CANCER RESEARCH
- Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
- (2013) Nitin Jain et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin
- (2013) Joachim Albers et al. JOURNAL OF CELL BIOLOGY
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Palliative surgery in patients with unresectable colorectal liver metastases: a propensity score matching analysis
- (2013) Yong Sik Yoon et al. JOURNAL OF SURGICAL ONCOLOGY
- VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
- (2013) E Terpos et al. LEUKEMIA
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Down-Regulation of Canonical and Up-Regulation of Non-Canonical Wnt Signalling in the Carcinogenic Process of Squamous Cell Lung Carcinoma
- (2013) Domokos Bartis et al. PLoS One
- Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
- (2013) Bo Hu et al. PLoS One
- Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
- (2012) E. Terpos et al. ANNALS OF ONCOLOGY
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Developmental Stage and Time Dictate the Fate of Wnt/β-Catenin-Responsive Stem Cells in the Mammary Gland
- (2012) Renée van Amerongen et al. Cell Stem Cell
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation
- (2012) N Giuliani et al. LEUKEMIA
- Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
- (2012) Noopur Raje et al. Clinical Interventions in Aging
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
- (2011) S. D'Souza et al. BLOOD
- Guidelines for the diagnosis and management of multiple myeloma 2011
- (2011) Jennifer M. Bird et al. BRITISH JOURNAL OF HAEMATOLOGY
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- (2011) Noopur Raje et al. CLINICAL CANCER RESEARCH
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
- (2011) Maurizio Zangari et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
- (2011) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
- (2011) Gareth J Morgan et al. LANCET ONCOLOGY
- A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
- (2011) S Vallet et al. LEUKEMIA
- Suppression of bone formation by osteoclastic expression of semaphorin 4D
- (2011) Takako Negishi-Koga et al. NATURE MEDICINE
- Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits—long-term efficacy outcomes
- (2010) Paula Garland et al. ANNALS OF HEMATOLOGY
- The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3
- (2010) Giacomina Brunetti et al. Annals of the New York Academy of Sciences
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
- (2010) J.-L. Harousseau et al. BLOOD
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
- (2010) K. Noonan et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells
- (2010) Lauren E. Mulcahy et al. BONE
- A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
- (2010) M. Zangari et al. HAEMATOLOGICA
- The amazing osteocyte
- (2010) Lynda F Bonewald JOURNAL OF BONE AND MINERAL RESEARCH
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
- (2010) Peter Gimsing et al. LANCET ONCOLOGY
- Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
- (2010) E Terpos et al. LEUKEMIA
- TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
- (2010) Kyoko Takeuchi et al. PLoS One
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling
- (2009) Y.-W. Qiang et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells
- (2009) Thomas L. Andersen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
- (2009) Sarah Deleu et al. CANCER RESEARCH
- Dickkopf-1: a suitable target for the management of myeloma bone disease
- (2009) Maria Gavriatopoulou et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
- (2009) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
- (2009) S Colucci et al. LEUKEMIA
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- (2008) Angela Pennisi et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone
- (2008) Thomas Levin Andersen et al. AMERICAN JOURNAL OF PATHOLOGY
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
- (2008) Y.-W. Qiang et al. BLOOD
- The pathogenesis of the bone disease of multiple myeloma
- (2008) Claire M. Edwards et al. BONE
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
- (2008) Masahiro Shinohara et al. CELL
- Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells
- (2008) F. Silvestris et al. CLINICAL CANCER RESEARCH
- Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
- (2008) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- 153Sm: its use in multiple myeloma and report of a clinical experience
- (2008) Elisabetta Abruzzese et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel targets for myeloma bone disease
- (2008) G David Roodman EXPERT OPINION ON THERAPEUTIC TARGETS
- Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck
- (2008) Kimberly M. Creach et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Building bone to reverse osteoporosis and repair fractures
- (2008) Sundeep Khosla et al. JOURNAL OF CLINICAL INVESTIGATION
- The cell biology of bone metabolism
- (2008) H K Datta et al. JOURNAL OF CLINICAL PATHOLOGY
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
- (2008) Huang Hongming et al. LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation